The tauopathies market is expected to be driven by the launch of a first-to-market drug, says a report by GlobalData.

Titled ‘PharmaFocus: Tauopathies – Global Market Analysis’, the report projects the launch of a first-to-market drug that will encourage pharmaceutical companies to focus their research and development (R&D) efforts on the market.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The tauopathies market includes more than 20 neurodegenerative diseases such as progressive supranuclear palsy and corticobasal degeneration caused by the aggregation of tau protein in the brain. No approved therapies are currently available to treat the disease.

“Approval of the first drug is expected to not only secure a high patient share, but also set an effective therapeutic approach and regulatory approval process for the market.”

Approval of the first drug is expected to not only secure a high patient share, but also set an effective therapeutic approach and regulatory approval process for the market.

A disease-modifying approach will extend patients’ lives and a symptomatic treatment will provide relief for patients. It will also make the market attractive for manufacturers, driving R&D investments and reducing the financial risk associated with development.

Additionally, approval of a tauopathy drug is expected to promote the off-label use for other indications further driving sales, according to GlobalData healthcare analyst Akiko Fukui, MSc. There is a strong possibility of expanding the sales of tauopathy drugs in the Alzheimer’s disease space, which can generate huge revenues for drug manufacturers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Four products to treat tauopathies are currently in late-stage development, including Avanir / Otsuka’s AVP-786, AB Sciences’ masitinib, TauRx Pharmaceuticals’ TRx-237, and Sellas / Catalent’s zolpidem. Additionally, a number of other products are in early / pre-clinical / discovery stages.